You are here: Industry Insights > ADC

News List

CStone presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 prnasia
October 13, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
Lonza Extends Collaboration for Monoclonal Antibody Supply at Scale americanpharmaceuticalreview
July 19, 2021
Lonza, a CDMO partner to the biopharma industry, announced the extension of its collaboration with a major biopharmaceutical partner for the commercial-scale manufacture of monoclonal antibodies, under a long-term agreement.
Lonza extends collaboration with biopharma client for antibody drug conjugate supply expresspharma
July 19, 2021
Lonza Group has extended collaboration with a major biopharma industry client for the supply of an antibody drug conjugate (ADC) against hard-to-treat cancers, the company said in a statement.
Novasep, Exelixis Ink ADC Manufacturing Agreement contractpharma
July 07, 2021
Covers the cGMP clinical manufacturing of a next-generation ADC drug candidate.
Innovent Biologics Signs License Agreement with Synaffix contractpharma
July 02, 2021
Synaffix will provide proprietary ADC technologies to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC candidate.
Innovent Announces License Agreement with Synaffix in an ADC Technology Deal prnasia
June 29, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced the signing of ...
Iksuda, LegoChem Expand ADC Alliance contractpharma
June 23, 2021
Grants Iksuda access to LegoChem's next generation ADC platform for up to six targets.
Eisai, BMS Enter Global Anticancer ADC Alliance contractpharma
June 21, 2021
Eisai Co., Ltd. and Bristol-Myers Squibb Co. entered an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
VERAXA and Quadira Enter ADC Development Partnership contractpharma
June 16, 2021
VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), an ADC engineering and functional antibody screening company, has entered into a partnership with Quadira Biosciences AG of Zug, Switzerland, to develop a suite of novel ADCs for the treatment of ...
WuXi XDC and LegoChem Ink ADC Agreement contractpharma
June 15, 2021
WuXi XDC, a global CDMO providing end-to-end bioconjugates services, and LegoChem Biosciences (LCB), signed a Memorandum of Understanding (MOU) for a partnership in development and manufacturing of antibody-drug conjugates (ADCs).

Previous page 1 2 3 4 5 6 7 8 9 10 Next page